
European Economic Area
European Economic Area
Northern IrelandBiocidal Products Regulation (BPR)
EU grants 10-year authorisation to LANXESS CMIT/MIT biocides, boosting industrial preservation across Europe from Nov 2024 to Oct 2034.
Published in November 2024. Dates, deadlines and stages may have changed since.
3 min readAI-drafted, expert reviewed

The European Commission has granted Union authorisation to the LANXESS CMIT/MIT Biocidal Product Family, effective from 17 November 2024 through 31 October 2034. This authorisation permits the use and marketing of the product family across EU member states, following Regulation (EU) No 528/2012 concerning biocidal products. The decision supports various industries with a reliable preservation solution for materials, cooling systems, and treatment fluids in manufacturing processes.
The authorised product family, produced by LANXESS Deutschland GmbH, features a blend of active substances, primarily a mixture of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (CMIT/MIT) at a 3:1 ratio. This formulation is approved for multiple applications, including:
PT06: Preservatives for products in storage,PT11: Preservatives for liquid-cooling and processing systems,PT12: Slimicides for paper production,PT13: Preservatives for working fluids in metal and glass treatment.
The LANXESS product family’s biocidal properties make it essential for industries seeking to protect products from microbial degradation and to maintain sterile environments across applications. Specific uses include:
The CMIT/MIT biocides authorised in the LANXESS product family require specific handling and risk mitigation measures due to potential health hazards, such as skin burns and respiratory tract irritation. The regulation mandates that all users wear protective gloves, clothing, and face protection during application. Additionally, the product’s high toxicity to aquatic life necessitates strict disposal and spill management protocols to prevent environmental contamination.
The LANXESS CMIT/MIT Biocidal Product Family's authorisation follows a comprehensive review by the European Chemicals Agency (ECHA) and reflects the Commission’s commitment to maintaining stringent health and safety standards in the biocidal product sector. The regulation aligns with EU objectives for safer chemical management and underscores the importance of innovation in materials preservation across various industries.
The authorisation remains valid for a decade, promoting industry adherence to sustainable practices while providing the EU market with a regulated and approved biocidal option. Future evaluations will determine its extended use, as industries increasingly adopt these biocides to enhance product safety and longevity.
This EU-wide authorisation positions LANXESS as a key contributor to biocidal applications in industrial and manufacturing environments, ensuring the safe preservation of critical materials and processes. With this decision, the European Commission reaffirms its dedication to high standards in biocidal applications, benefiting both industry stakeholders and the environment.
Official source
eur-lex.europa.eu
Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanForesight follows changes like this one and shows where they reach your substances, products and markets.

European Economic Area

European Economic Area

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at